



Final Appraisal Recommendation

Advice No: 1514 – June 2014

Emtricitabine/rilpivirine/tenofovir disoproxil (as fumarate) (Eviplera®) 200 mg/25 mg/245 mg film-coated tablet

Limited submission by Gilead Sciences Ltd

Recommendation of AWMSG

Emtricitabine/rilpivirine/tenofovir disoproxil (Eviplera®) is recommended as an option for use within NHS Wales for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load $\leq 100,000$ HIV-1 RNA copies/mL. Genotypic resistance testing and/or historical resistance data should guide the use of emtricitabine/rilpivirine/tenofovir disoproxil (Eviplera®).

Additional note:

- This advice incorporates and replaces the existing AWMSG recommendation on emtricitabine/rilpivirine/tenofovir disoproxil (Eviplera®) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve adult patients (Advice number 1412, originally published August 2012).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2374), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Gilead Sciences Ltd
Date of first issue	June 2014
Last reviewed	September 2017



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1514:
Emtricitabine/rilpivirine/tenofovir disoproxil (as fumarate) (Eviplera®)

